CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 20 enrolled
Drug / intervention
alteplase (recombinant t-PA) +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03672006
NCT03672006Phase 2Completed
CompareCT.gov

Tissue Plasminogen Activator Dwells to Reduce Catheter-associated Thrombosis and Infection

Medical College of Wisconsin·interventional·Posted Sep 14, 2018·Updated Jul 13, 2021

In Brief

A Phase 2 clinical trial evaluating alteplase (recombinant t-PA) and Heparin for Central Venous Catheter Thrombosis and Central Venous Catheter Associated Bloodstream Infection. Completed, enrolled 20 participants across 1 site.

Detailed Summary

The purpose of this pilot study is to test feasibility of concept, consent and enrollment rates, and mechanics of study designed to assess if intra-catheter dwells of tissue plasminogen activator (t-PA) is effective in decreasing the rate of clinically diagnosed central line associated blood stream infection (CLABSI) or venous thromboembolism (VTE) in central venous catheters (CVC) compared to standard of care heparin dwell.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCentral Venous Catheter Thrombosis, Central Venous Catheter Associated Bloodstream Infection
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedSep 14, 2018
Enrollment StartApr 22, 2019
Primary CompletionDec 15, 2019
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 7.8 years ago

Interventions

alteplase (recombinant t-PA)biological

Medication administered to dwell in central venous catheter

Heparindrug

Medication administered to dwell in central venous catheter